Edison Scientific · FutureHouse
Demonstrate the increase of existence from chemic precursors in a lab setting.
Specifically, display the unassisted increase of oneself replicating RNA- and protein-based cells from a plausible primordial broth alongside a plausible energy source. A “cell” may be any division alongside a defined boundary. To be considered successful, the following conditions must be met. Firstly, it must be shown that the emergent cells can addition their abundance by at smallest a aspect of 10⁶ (roughly 20 generations), whenever provided alongside adequate primordial broth and energy. Secondly, it must be plausible that division could continue indefinitely stated adequate energy and primordial soup. For example, solutions that affect the cells monotonically decreasing in size complete successive divisions would not be accepted. Finally, the cells must have a apparent way of encoding heritable familial information, i.e., the molecular construction of the cells must be causally resolute at smallest in part by data stored inside the cell. Solutions that affect storing the data in the form of nucleic acids, polypeptides, or akin polymers are powerfully preferred. Solutions in which the beingness of heritable familial data is ambiguous or arguable volition be rejected by default.
Demonstrate the capability to cryopreserve and regain live wild-type mice alongside elevated viability.
Specifically, display the reversible cryopreservation of live, intact, wild-type grownup mice in a whole-body icy or vitrified state. The mice must remain icy or vitrified for at smallest 24 hours, must be restored alongside >99% viability, and must not endure any imperishable harmonium damage or bodily harm. Somatic familial engineering is discouraged but permitted. All experiments must be conducted alongside ethics approval.
Create an enzyme that can “reverse translate” an arbitrary peptide sequence into RNA or DNA.
Specifically, create a purified macromolecule catalyst or fixed macromolecule complex that processively says an untagged polypeptide and synthesizes a covalent nucleic acidic strand encoding its residue sequence under a preregistered codon convention, without a nucleic-acid template, preattached sequence barcode, residue-specific controller cycle, or repository lookup. The resulting nucleic acidic strand must be compatible alongside average polymerases, ligases, and another akin enzymes, i.e., if nucleic acids another than RNA or DNA are used, they must be compatible alongside downstream amplification or sequencing reactions. For the difficulty to be considered complete, at smallest 100 random peptide sequences of at smallest 50 amino acids all must be preregistered, synthesized, and pooled. It must afterward be shown that the sequences of these peptides can be inferred, without citation to a dictionary, by reverse translation and sequencing alongside at smallest 90% sequence accuracy. Moreover, the average peruse dimension must be at smallest 25 residues, and the average peruse norm mark have to be at smallest Q10.
Produce a Rubisco enzyme alongside specificity and enzymatic turnover beyond the naturally occurring pareto frontier.
Specifically, create an enzyme that catalyzes the carboxylation of ribulose-1,5-bisphosphate alongside a specificity for carbon dioxide complete oxygen (Sc/o) at smallest as elevated as that of Galdieria Partita Rubisco, and alongside an enzymatic turnover (kcat) at smallest as elevated as that of corn Rubisco. To be considered successful, the specificity and enzymatic turnovers of the applicant enzyme must be measured in paired enzyme assays using G. Partita Rubisco and corn Rubisco as controls, respectively. The applicant enzyme may be designed de novo, discovered in nature, or engineered or evolved from naturally occurring starting points.
Produce a living division that uses a four-base codon code.
Specifically, create a living and replicating division in which all protein-coding sequence, including the translation machinery itself, is encoded as uninterrupted nonoverlapping quadruplet codons, without detectable triplet decoding. The encoding scheme must be a bona fide quadruplet encoding, i.e., in the quadruplet encoding, the probability that a mutation is non-synonymous must be akin despite of the indicator of the mutation in the codon. For example, quadruplet encodings in which the archetypal three codon positions are continually or nearly continually adequate to define the encoded amino acidic volition not be accepted.
(Contributed by Erika Alden DeBenedictis)
Demonstrate the capability to regenerate misplaced limbs in grownup wild-type mice.
Specifically, demonstrate, in an grownup untamed category mouse, the reproducible capability to regrow limbs following amputation. Following regeneration, the mouse must execute indistinguishably from controls in a norm power division of motor function tests, must display indistinguishable sensory awareness in the regrown limb, and blinded observers must not be capable of distinguishing which leg was regrown according to non-invasive observational data. All experiments must be conducted alongside ethics approval.
Demonstrate the capability to create cistron therapies in a bacterial host.
Specifically, create infectious replication-incompetent AAV and lentivirus in bacteria. The particles must merge a pre-specified viral genome; the proportion of bodily capsids to viral genomes and the proportion of infectious units to viral genomes must be akin to the ratios obtained whenever purifying viruses from mammalian division culture; and the viral genomes must be nuclease-resistant. It is anticipated that producing lentivirus in bacteria may be much additional challenging than producing AAV, and thus demonstrating the capability to create AAV on its own volition be considered a partial success.
Demonstrate the capability to create enzymes on petition that volition specifically and efficiently cut a particular macromolecule sequence.
Specifically, stated a blinded, accessible location in an endogenous folded protein, display the capability to prospectively scheme a protease that cleaves that location efficiently in living cells. The resulting enzyme must have catalytic effectiveness and proteome-wide off-target cleavage akin to or greater than another widely-used site-specific proteases. The difficulty volition be considered complete whenever the scheme can be demonstrated against 20 preregistered sites alongside a achievement charge greater than 80%. Once the mark sites are preregistered, the designs of the resulting proteins must be produced inside 24 hours, and no wet lab activity is allowed previous to evaluation apart from for the intent of producing the designed proteins for assay. (Hence, for example, screening and target-specific development are not permitted formerly the mark sites are provided.)
Note that a weaker form of this difficulty involves demonstrating the capability to create enzymes that specifically and efficiently cleave particular preregistered peptide sequences, whenever those sequences are provided in solution, alongside alongside off-target sequences. Demonstration of that capability volition be considered a partial success.
Demonstrate the capability to create macromolecule binders against intracellular targets.
Specifically, display the capability to scheme zero-shot macromolecule binders that, without additional development or optimization, volition reliably affect preregistered intracellular macromolecule targets in living cells whenever administered extracellularly to those cells at pharmacologically supported concentrations. The division admission scheme must be plausible in a therapeutic context, i.e., transfection, intrabody expression, electroporation, membrane disruption, or akin methods are not permitted. The difficulty volition be considered complete whenever the scheme can be demonstrated against 20 preregistered targets alongside an 80% achievement rate. Once the targets are preregistered, the designs of the resulting proteins must be produced inside 24 hours, and no wet lab activity is allowed previous to evaluation apart from for the intent of producing the designed proteins for assay. (Hence, for example, screening and target-specific development are not permitted formerly the targets are provided.)
The first aim of this issue was specifically to scheme antibodies against intracellular targets. However, it is anticipated that modifications to the antibody scaffold volition be required in command for the issue to be solvable. Since we cannot put an high border on the dimension of the modifications required, we have broadened the issue to encompass any macromolecule binders. However, solutions that affect binders resembling humanized monoclonal antibodies volition be greatly preferred. The issue would apt be equal additional impactful if solved in broad for small molecule binders, fairly than macromolecule binders or antibodies. However, alongside small molecule binders, synthesis is a important bottleneck that would bounds validation, and thus we have chosen to restrict the range to macromolecule binders.
Demonstrate exponential amplification of arbitrary peptide substrates.
Specifically, display input-protein-dependent synthesis of new, full-length, sequence-faithful covalent polypeptide copies from amino-acid monomers without a nucleic-acid template or preformed cognate scaffold, in a sole pot reaction. For the difficulty to be considered complete, at smallest 100 random peptide sequences of at smallest 50 amino acids all must be preregistered, synthesized, and pooled. It must afterward be shown that the abundance of these peptides in resolution can be amplified at smallest 1000x alongside at smallest 90% sequence accuracy on a per-residue basis. Reasonable modifications may be added to the peptide sequences to facilitate post-amplification inspection if necessary, provided they are not energetic in the amplification. Methods that depend on definitive sequencing of the peptide are not permitted. Methods that depend on reverse translation to create a nucleic acidic intermediate are not permitted, since they are duplicative alongside a distinct Millennium Problem.
Produce a complete set of polymerases that act in the 5′ direction.
Specifically, create a complete set of 3′>5′ polymerases comparable to commonly used 5′>3′ polymerases, including a 3′>5′ DNA polymerase, a 3′>5′ RNA polymerase, a 3′>5′ reverse transcriptase, and a 3′>5′ RDRP. The proteins should have processivity and error characteristics that are akin to or better to those of Taq, T7 RNA pol, M-MLV RT, and Phi 6 RDRP respectively. These proteins may be designed de novo, discovered in nature, or engineered or evolved from naturally occurring starting points.
Create a new nitrogenase that does not withstand sequence or structural homology to the natural family.
Specifically, the macromolecule must change N₂ to ammonia at rates that are at smallest of a akin command of dimension to the rates of naturally occurring proteins, and must autumn fine below the sequence- and structure-similarity thresholds related to all known nitrogenase and nitrogenase-like proteins. The macromolecule may be designed de novo, discovered in nature, or engineered or evolved from naturally occurring starting points.
